Immuron Valuation

Is IMC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IMC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IMC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IMC's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IMC?

Key metric: As IMC is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for IMC. This is calculated by dividing IMC's market cap by their current revenue.
What is IMC's PS Ratio?
PS Ratio	3.5x
Sales	AU$4.90m
Market Cap	AU$17.19m

IMC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.2x
Enterprise Value/EBITDA	-1.1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does IMC's PS Ratio compare to its peers?

The above table shows the PS ratio for IMC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	7.7x
TRP Tissue Repair	8.8x	n/a	AU$16.0m
CHM Chimeric Therapeutics	1.1x	n/a	AU$9.1m
BDX BCAL Diagnostics	12.7x	77.6%	AU$37.7m
PTX Prescient Therapeutics	8.2x	n/a	AU$31.4m
IMC Immuron	3.5x	59.7%	AU$17.2m

Price-To-Sales vs Peers: IMC is good value based on its Price-To-Sales Ratio (3.5x) compared to the peer average (7.7x).

Price to Sales Ratio vs Industry

How does IMC's PS Ratio compare vs other companies in the AU Biotechs Industry?

8 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	10.0x	8.3%
IMC Immuron	3.5x	59.7%	US$11.17m
ARX Aroa Biosurgery	3.6x	20.1%	US$142.40m
ATH Alterity Therapeutics	4x	25.0%	US$10.38m

8 Companies		Estimated Growth	Market Cap
Industry Avg.	10.0x	15.3%
IMC Immuron	3.5x	22.4%	US$11.17m

No more companies

Price-To-Sales vs Industry: IMC is good value based on its Price-To-Sales Ratio (3.5x) compared to the Australian Biotechs industry average (10x).

Price to Sales Ratio vs Fair Ratio

What is IMC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IMC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.5x
Fair PS Ratio	13.2x

Price-To-Sales vs Fair Ratio: IMC is good value based on its Price-To-Sales Ratio (3.5x) compared to the estimated Fair Price-To-Sales Ratio (13.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Little Green Pharma

AU$39.2m

Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.

LGP

AU$0.13

6.1%

AVITA Medical

US$339.9m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.92

2.3%

25.0%

AVITA Medical

US$342.3m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.97

0.3%

19.6%